Daily Archives: April 7, 2022 | LinksMedicus Free Medical News & Perspectives

Study finds increased risk of pulmonary embolism up to 110 days after COVID-19.

7 Apr, 2022 | 10:06h | UTC

Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study – The BMJ

News Release: Study finds increased risk of serious blood clots up to six months after COVID-19 – BMJ

Editorial: Thromboembolism and bleeding after covid-19

Commentary: Covid: Blood clot risk higher for six months after having virus – BBC

M-A: Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization.

7 Apr, 2022 | 09:55h | UTC

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: Common Antidepressant Likely Cuts Risk Of Covid Hospitalization, Study Finds – Forbes

Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Commentary on Twitter

Bayesian SRMA of 3 RCTs showed a high prob (94-98.6%) that fluvoxamine is associated with reduced risk of hospitalization for outpatients with #COVID19, (RR 0.75). @DrEmilyMcD @DrToddLee @simonevigod @AngelaReiersen @boulware_dr https://t.co/ctMKzBDbzP

— JAMA Network Open (@JAMANetworkOpen) April 6, 2022

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

7 Apr, 2022 | 10:00h | UTC

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

Commentary on Twitter (thread – click for more)

#JustPublished!#ECDC and @EMA_News issue advice on fourth doses of mRNA #COVID19 vaccines.

Read the full joint statement: https://t.co/hBuOlrfKOD pic.twitter.com/aO5vSyYvTk

— ECDC (@ECDC_EU) April 6, 2022

Pragmatic RCT: In outpatients with Covid-19, the addition of pulse oximetry for monitoring did not improve outcomes compared to subjective assessments of dyspnea alone.

7 Apr, 2022 | 09:58h | UTC

Pulse Oximetry for Monitoring Patients with Covid-19 at Home — A Pragmatic, Randomized Trial – New England Journal of Medicine

Commentary on Twitter

A potential practice changer by @kit_delgadoMD et al in NEJM today.

At-home pulse oximeters did NOT improve outcomes.

Important to focus on things that help.

If these devices don't help, then we shouldn't routinely advise them.

Super interesting work.https://t.co/VDDyRLw7ba

— Jeremy Faust MD MS (ER physician) (@jeremyfaust) April 6, 2022

RCT: Among patients with complicated urinary tract infection, oral Tebipenem Pivoxil Hydrobromide was noninferior to intravenous Ertapenem and showed a similar safety profile.

7 Apr, 2022 | 09:53h | UTC

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

For complicated UTI or acute pyelonephritis, oral tebipenem pivoxil hydrobromide noninferior to IV ertapenem and has a similar safety profile. https://t.co/FRDMQOD0Pn pic.twitter.com/GFQz7SlciX

— NEJM (@NEJM) April 6, 2022

RCT: Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne Muscular Dystrophy.

7 Apr, 2022 | 08:53h | UTC

Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial – JAMA (free for a limited period)

RCT: Routine lung volume recruitment is not beneficial for boys with Duchenne muscular dystrophy.

Phase 2 RCT: Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy.

Research: Long-term effects of glucocorticoids in patients with Duchenne muscular dystrophy

Commentary on Twitter

In this randomized clinical trial of boys with Duchenne muscular dystrophy, treatment with daily #prednisone or daily #deflazacort resulted in significantly better outcomes compared with intermittent prednisone. https://t.co/rKjSrjVemR #AAN2022 pic.twitter.com/qPNV9KBOXv

— JAMA (@JAMA_current) April 5, 2022

Opinion: The medical algorithmic audit.

7 Apr, 2022 | 09:51h | UTC

The medical algorithmic audit – The Lancet Digital Health

Linked Article: Validation and algorithmic audit of a deep learning system for the detection of proximal femoral fractures in patients in the emergency department: a diagnostic accuracy study – The Lancet Digital Health

Commentary on Twitter

“without the ability to observe and learn from algorithmic errors, the risk is that it will continue to happen and there's no accountability for any harm that results"
NEW Editorial: 'Holding #ArtificialIntelligence to account'.https://t.co/Dg3OtJZZT9 pic.twitter.com/JQbrXbbNqy

— The Lancet Digital Health (@LancetDigitalH) April 6, 2022

Randomized, sham-controlled trial: Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs.

7 Apr, 2022 | 09:49h | UTC

Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial – The Lancet (link to abstract – $ for full-text)

Commentary: Three-year trial of SPYRAL HTN-ON MED shows blood pressure reductions – MedicalXpress

Systematic Review: Renal denervation may have a modest effect in improving 24h ambulatory blood pressure monitoring (reduction in SBP by 5.29 mmHg and DBP by 3.75 mmHg) but does not improve major cardiovascular outcomes and renal function.

M-A: Renal denervation for hypertension is associated with a modest reduction in ambulatory blood pressure control (3.61 mm Hg reduction in ambulatory systolic BP and 1.85 mm Hg reduction in ambulatory diastolic BP).

#ACC21 – RCT: Among patients with resistant hypertension, ultrasound renal denervation resulted in a modest improvement in systolic BP (–4.5 mm Hg) vs. sham procedure.

Meta-Analysis: Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients with Hypertension

Commentary on Twitter

Renal denervation could provide an adjunctive treatment modality in the management of patients with #hypertension, suggests trial assessing long-term efficacy & safety in the presence of antihypertensive drugs: https://t.co/45ojbyhQp3 pic.twitter.com/eg6CXGDGCE

— The Lancet (@TheLancet) April 6, 2022

Perspective | Studying severe long COVID to understand post-infectious disorders beyond COVID-19.

7 Apr, 2022 | 08:45h | UTC

Studying severe long COVID to understand post-infectious disorders beyond COVID-19 – Nature Medicine

Review: Post-acute COVID-19 syndrome.

ESCMID rapid guidelines for assessment and management of long COVID.

ERS statement on Long COVID-19 follow-up.

Proposed subtypes of long-Covid and their respective potential therapies.

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play.

Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.

The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

COVID-19 infections increase risk of heart conditions up to a year later, study finds.

Commentary from the author on Twitter (thread – click for more)

1/ HGE (https://t.co/VMUVMAo1bJ) position paper on #LongCOVID #PACS . By focusing on the most severe patients, w severe organ damage/dysfunction following mild/moderate #COVID19 – we will search for genetic and immunological mechanisms of disease https://t.co/dZQPEoNkhl pic.twitter.com/tgblk7oFQG

— Petter Brodin (@BrodinPetter) April 5, 2022

Perspective | An equitable roadmap for ending the COVID-19 pandemic.

7 Apr, 2022 | 08:48h | UTC

An equitable roadmap for ending the COVID-19 pandemic – Nature Medicine

Commentary on Twitter

A Comment article in @NatureMedicine argues that the COVID-19 pandemic will end only with a renewed focus on equitable distribution of vaccines and therapeutics, responsive public health plans, and policies to protect the vulnerable. https://t.co/2cZShdqnY3

— Nature Portfolio (@NaturePortfolio) April 6, 2022

RCT: Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anesthetic injection for hip osteoarthritis.

7 Apr, 2022 | 08:37h | UTC

Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anaesthetic injection in addition to advice and education for hip osteoarthritis (HIT trial): single blind, parallel group, three arm, randomised controlled trial – The BMJ

News Release: Steroid injections may provide longer lasting benefits for hip pain than current best care – BMJ

Commentary on Twitter

Adding an ultrasound guided corticosteroid and local anaesthetic injection to advice and education offers rapid and sustained improvements in pain and function, finds new research https://t.co/fQHzvKv2wL

— The BMJ (@bmj_latest) April 7, 2022

WHO Strategic framework for collaboration on antimicrobial resistance.

7 Apr, 2022 | 08:41h | UTC

Strategic framework for collaboration on antimicrobial resistance – World Health Organization

Four priority actions to slow the silent pandemic of antimicrobial resistance.

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.

Perspective | The hidden epidemic: Antibiotic resistance is approaching a crisis point, and the world needs to act.

Commentary on Twitter

#DYK: Drug resistant organisms are found in people, animals, food, plants and the environment.
That's why WHO works in collaboration with @FAO, @OIEAnimalHealth & @UNEP to address #AntimicrobialResistance https://t.co/enhUb1jg2g pic.twitter.com/9elCBspx4y

— World Health Organization (WHO) (@WHO) April 6, 2022

RCT: Pain outcomes following mechanochemical ablation vs. cyanoacrylate adhesive for the treatment of primary truncal saphenous vein incompetence.

7 Apr, 2022 | 08:28h | UTC

Pain Outcomes Following Mechanochemical Ablation vs Cyanoacrylate Adhesive for the Treatment of Primary Truncal Saphenous Vein Incompetence: The MOCCA Randomized Clinical Trial – JAMA Surgery (free for a limited period)

Invited Commentary: Relevant Outcomes in Superficial Venous Ablation Treatments – JAMA Surgery (free for a limited period)

Commentary on Twitter

Randomized clinical trial comparing mechanochemical ablation to cyanoacrylate adhesive found that both techniques have similar peri-procedural pain score. https://t.co/Oq0U7HqoZR @amjad_belramman

— JAMA Surgery (@JAMASurgery) April 6, 2022

RCT: Effect of intramuscular vs. intra-articular glucocorticoid injection on pain among adults with knee osteoarthritis.

7 Apr, 2022 | 08:35h | UTC

Effect of Intramuscular vs Intra-articular Glucocorticoid Injection on Pain Among Adults With Knee Osteoarthritis: The KIS Randomized Clinical Trial – JAMA Network Open

Commentary on Twitter

This RCT found IM steroid injections were inferior to intrarticular injections for reducing pain in patients with knee osteoarthritis at 4 weeks but were noninferior at 8 and 24 weeks after injection. https://t.co/opq1C2BP8c pic.twitter.com/ucx4lvRDJQ

— JAMA Network Open (@JAMANetworkOpen) April 5, 2022

Cohort Study: Comparison of rates of Type 2 Diabetes in adults and children treated with anticonvulsant mood stabilizers.

7 Apr, 2022 | 08:32h | UTC

Comparison of Rates of Type 2 Diabetes in Adults and Children Treated With Anticonvulsant Mood Stabilizers – JAMA Network Open

Commentary on Twitter

This cohort study found that the choice of which anticonvulsant mood stabilizer to initiate may have meaningful reductions in type 2 diabetes incidence; valproate was associated with the highest risk and lamotrigine the lowest. https://t.co/pyME0G25wt

— JAMA Network Open (@JAMANetworkOpen) April 6, 2022

Retinal photograph-based deep learning predicts biological age, and stratifies morbidity and mortality risk.

7 Apr, 2022 | 08:18h | UTC

Retinal photograph-based deep learning predicts biological age, and stratifies morbidity and mortality risk – Age and Ageing

M-A: Efficacy of dezocine on preventing opioid-induced cough during general anesthesia induction.

7 Apr, 2022 | 08:15h | UTC

Efficacy of dezocine on preventing opioid-induced cough during general anaesthesia induction: a PRISMA-compliant systematic review and meta-analysis – BMJ Open

Systematic Review: Diagnostic and prognostic factors in patients with prostate cancer.

7 Apr, 2022 | 08:16h | UTC

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review – BMJ Open

Case-cohort study: The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China.

7 Apr, 2022 | 08:22h | UTC

The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study – The Lancet Public Health

Commentary: Helicobacter pylori infection and risk of gastric cancer – The Lancet Public Health

Review: Mechanisms of action of current pharmacologic options for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.

7 Apr, 2022 | 08:14h | UTC

Mechanisms of Action of Current Pharmacologic Options for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation – American Journal of Gastroenterology

Cohort study: Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy.

7 Apr, 2022 | 08:09h | UTC

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy – Journal of Clinical Oncology

Commentary on Twitter

Out now @JCO_ASCO huge effort of our team and @TILsWorkGroup: Excellent prognosis of TNBC pts with high TILs even without chemo! Chemo de-escalation trials urgently needed! # bcsm https://t.co/42eUZaA2vo

— MarleenKokLab (@lab_kok) March 31, 2022

M-A: Immediate and sustained outcomes and moderators associated with metacognitive training for psychosis.

7 Apr, 2022 | 08:10h | UTC

Immediate and Sustained Outcomes and Moderators Associated With Metacognitive Training for Psychosis: A Systematic Review and Meta-analysis – JAMA Psychiatry

Commentary: Therapy Challenging Cognitive Biases Reduces Symptoms of Psychosis, Meta-Analysis Suggests – Psychiatry News Alert

Recommendations for reporting results of diagnostic genomic testing.

7 Apr, 2022 | 08:02h | UTC

Recommendations for reporting results of diagnostic genomic testing – European Journal of Human Genetics

RCT: In patients undergoing intraarterial treatment for stroke, functional outcomes after 3 months were similar with general anesthesia vs. sedation.

7 Apr, 2022 | 08:00h | UTC

General Anesthesia versus Sedation, Both with Hemodynamic Control, during Intraarterial Treatment for Stroke: The GASS Randomized Trial – Anesthesia

Commentary on Twitter

Previous speculations have considered the relationship between anesthetic strategy and patient outcomes. Now, new research suggests general #anesthesia and #sedation produce comparable outcomes after endovascular treatment for stroke. https://t.co/ggLRO8Or3W pic.twitter.com/dLLGA4Vmgk

— Anesthesiology journal (@_Anesthesiology) March 24, 2022

Systematic Review: Algorithm‐based pain management for people with dementia in nursing homes.

7 Apr, 2022 | 07:52h | UTC

Algorithm‐based pain management for people with dementia in nursing homes – Cochrane Library

Summary: Step-by-step (algorithm-based) pain management for people with dementia living in nursing homes – Cochrane Library

Stay Updated in Your Specialty